Analyzing the Q3 vs. Q4 2022 13F Holdings for CPMG Inc: Winners and Losers in Investment Portfolio.

As the saying goes, "the only constant in life is change." This rings true in the world of finance, where stock market volatility and investor sentiment can quickly shift holdings in investment portfolios. One way to gain insight into these changes is through analyzing quarterly reports of fund holdings, such as the 13F filings required by the Securities and Exchange Commission (SEC). In this post, we will examine the Q3 2022 vs. Q4 2022 13F Holdings Comparison for CPMG Inc, a fund that invests in a variety of publicly traded companies.

First, let's consider the overall trend in the fund's holdings between Q3 2022 and Q4 2022. As we can see from the CSV data, the total value of the fund's holdings decreased from $875,050,000 in Q3 2022 to $788,241,000 in Q4 2022, a decline of 9.9%. This suggests that the fund may have liquidated some of its assets during this time period, possibly in response to market conditions or changes in investment strategy.

Next, let's examine the individual holdings that saw the most significant changes between Q3 and Q4. One stock that stands out is PROCEPT BIOROBOTICS CORP (PRCT), in which the fund's holdings decreased from 9,055,341 shares in Q3 to 5,328,867 shares in Q4, a decline of 41%. This decrease in shares held is also reflected in the declining value of the stock, which dropped from $375,434,000 in Q3 to $221,361,000 in Q4. It is unclear why the fund reduced its holdings in PRCT, but it may indicate a lack of confidence in the company's future prospects or a shift in investment strategy.

In contrast, the fund's holdings in REATA PHARMACEUTICALS INC (RETA) remained stable between Q3 and Q4, with no change in the number of shares held at 2,896,901. However, the value of these shares increased by 51.2%, from $72,799,000 in Q3 to $110,053,000 in Q4. This suggests that the fund has confidence in RETA's earnings potential and is willing to hold onto its position in the company.

Another stock that saw significant changes in the fund's holdings between Q3 and Q4 is APOLLO ENDOSURGERY INC (APEN). Here, the fund's holdings increased from 3,963,641 shares in Q3 to 6,183,603 shares in Q4, an increase of 55.9%. This increase in shares held is also reflected in the stock's rising value, which increased from $21,840,000 in Q3 to $61,650,000 in Q4, a rise of 182.3%. This may indicate that the fund is bullish on APEN's future prospects and sees potential for significant earnings growth.

One final stock to consider is INSTIL BIO INC (TIL), which saw a significant decrease in the fund's holdings between Q3 and Q4. The number of shares held remained consistent at 8,218,467, but the value of these shares dropped from $39,777,000 in Q3 to $5,177,000 in Q4, a decline of 87%. This significant drop in value suggests that the fund may have lost confidence in TIL's potential for earnings growth or faced other challenges with its investment in the company.

In conclusion, the Q3 2022 vs. Q4 2022 13F Holdings Comparison for CPMG Inc reveals a mixed picture of the fund's investment activity. While the overall value of holdings decreased, individual stocks like RETA and APEN saw significant increases in value, indicating confidence in their future prospects. In contrast, stocks like PRCT and TIL saw significant declines in value, suggesting that the fund may have reduced its holdings due to lack of confidence or other challenges. By analyzing these quarterly reports, investors can gain valuable insight into the activities and strategies of leading investment funds like CPMG Inc.